临床试验/NCT05722912

NCT05722912Approved For Marketing不适用

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Incyte Corporation0 个研究点开始时间: 2023年2月10日最近更新: 2023年2月10日

适应症

相关药物

试验速览

阶段: 不适用
状态: Approved For Marketing
发起方: Incyte Corporation

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

研究设计

研究类型: Expanded Access

入排标准

入选标准

未提供

排除标准

未提供

研究者

发起方

Incyte Corporation

申办方类型

Industry

责任方

Sponsor

相似试验

Approved For Marketing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantGraft-versus-host Disease (GVHD)

NCT03147742Incyte Corporation

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)Alopecia Areata

NCT05522556Pfizer

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisAtopic Dermatitis

NCT03745638Incyte Corporation631

No Longer Available

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 InfectionCOVID-19

NCT04355793Incyte Corporation

Ruxolitinib In GvHDGraft vs Host Disease

NCT02396628Prof. Dr. Nikolas von Bubnoff22

Expanded Access of Ruxolitinib Cream to Treat a... | 临床试验